Metformin in patients with hepatocellular carcinoma receiving immunotherapy

Metformin treatment rescues CD8+ T cell response to immune checkpoint inhibitor therapy in mice with NAFLD

(2022) Simon Wabitsch et al.   JOURNAL OF HEPATOLOGY

Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma

(2022) Landon L. Chan et al.   Cancers

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

(2021) Dominik Pfister et al.   NATURE

Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma

(2019) Lena Schulte et al.   LIVER INTERNATIONAL

Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes

(2019) Jian Zhou et al.   Annals of Hepatology

Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale

(2017) Andrea Casadei Gardini et al.   EUROPEAN JOURNAL OF CANCER

Metformin—mode of action and clinical implications for diabetes and cancer

(2014) Ida Pernicova et al.   Nature Reviews Endocrinology